List view / Grid view
Researchers have found that mitochondrial dysfunction in the blood-brain barrier may drive neuropsychiatric disease in 22q11.2 deletion syndrome – and that a cholesterol drug could restore barrier function and ease symptoms.
Scientists at Ghent University have discovered that a simple combination of vitamin B1 and glucose could drastically improve survival in sepsis – a life-threatening condition responsible for millions of deaths each year.
Scientists have discovered that cancer cells generate an instant burst of energy when physically squeezed, helping them repair DNA damage and survive harsh environments. This discovery means that therapies targeting this new survival mechanism could be developed.
Scientists at Lund University have shown that aggressive melanoma tumours are driven by overactive mitochondrial processes – revealing a potential treatment strategy using drugs already approved for other conditions.
MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.
Japanese researchers have developed a new enzyme technology that can precisely alter the levels of mutated mitochondrial DNA in patient-derived stem cells, offering a promising new approach for treating mitochondrial disorders.
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
Researchers have developed the world’s first animal model with A-to-G mtDNA edits achieved using engineered TALEDs.
For the first time, mitochondrial DNA mutations could be used with immunotherapy to increase the chances of successful treatments.
Treating C. elegans with inhibitors of small or large mitochondrial ribosomes extended their median lifespan.
